2021

Journal Articles- Refereed

K Degeling, NM Corcoran, A Pereira-Salgado, AA Hamid, S Siva, M IJzerman. Lifetime health and economic outcomes of active surveillance, radical prostatectomy, and radiotherapy for favorable-risk localized prostate cancer. Value in Health 24 (12), 1737-1745

RK Mahar, MB McGuinness, B Chakraborty, JB Carlin, MJ IJzerman, ... A scoping review of studies using observational data to optimise dynamic treatment regimens. BMC medical research methodology 21, 1-13

G Chazan, F Franchini, M Alexander, S Banerjee, L Mileshkin, P Blinman, ... M IJzerman, BJ Solomon. Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. ESMO open 6 (5), 100224

YH To, K Degeling, S Kosmider, R Wong, M Lee, C Dunn, G Gard, A Jalali, ... M IJzerman, P Gibbs, J Tie. Circulating tumour DNA as a potential cost-effective biomarker to reduce adjuvant chemotherapy overtreatment in stage II colorectal cancer. Pharmacoeconomics 39 (8), 953-964

A Pereira-Salgado, EM Kwan, B Tran, P Gibbs, J De Bono, M IJzerman. Systematic review of efficacy and health economic implications of real-world treatment sequencing in prostate cancer: where do the newer agents enzalutamide and abiraterone fit in?. European urology focus 7 (4), 752-763

K Degeling, A Pereira-Salgado, NM Corcoran, PC Boutros, P Kuhn, ... MJ IJzerman. Health economic evidence for liquid-and tissue-based molecular tests that inform decisions on prostate biopsies and treatment of localised prostate cancer: a systematic review. European Urology Open Science 27, 77-87

M Vu, K Degeling, M Martyn, E Lynch, B Chong, C Gaff, MJ IJzerman. Evaluating the resource implications of different service delivery models for offering additional genomic findings. Genetics in Medicine 23 (4), 606-613

J Zhang, J Li, S Xiong, Q He, RJ Bergin, JD Emery, MJ IJzerman, ... Global burden of lung cancer: implications from current evidence. Annals of Cancer Epidemiology 5

H Koffijberg, K Degeling, MJ IJzerman, VMH Coupé, MJE Greuter. Using metamodeling to identify the optimal strategy for colorectal cancer screening. Value in health 24 (2), 206-215

MJ IJzerman, J de Boer, A Azad, K Degeling, J Geoghegan, C Hewitt, ... . Towards routine implementation of liquid biopsies in cancer management: it is always too early, until suddenly it is too late. Diagnostics 11 (1), 103, 2021

K Degeling, NN Baxter, J Emery, MA Jenkins, F Franchini … M IJzerman. An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic. Asia‐Pacific Journal of Clinical Oncology, 2021